Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Obstructive Sleep Apnea - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obstructive Sleep Apnea - Pipeline Review, H2 2016, provides an overview of the Obstructive Sleep Apnea (Respiratory) pipeline landscape. Obstructive sleep apnea is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. Signs and symptoms of obstructive sleep apnea include excessive daytime sleepiness, awakening with chest pain, morning headache, high blood pressure, awakening with a dry mouth. Risk factors include being overweight, hypertension, diabetes, gender, smoking and family history. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obstructive Sleep Apnea - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Obstructive Sleep Apnea (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.Obstructive Sleep Apnea. Obstructive Sleep Apnea (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Obstructive Sleep Apnea (Respiratory). - The pipeline guide reviews pipeline therapeutics for Obstructive Sleep Apnea (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Obstructive Sleep Apnea (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Obstructive Sleep Apnea (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Obstructive Sleep Apnea (Respiratory) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Obstructive Sleep Apnea (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Obstructive Sleep Apnea (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Obstructive Sleep Apnea Overview 6 Therapeutics Development 7 Pipeline Products for Obstructive Sleep Apnea - Overview 7 Obstructive Sleep Apnea - Therapeutics under Development by Companies 8 Obstructive Sleep Apnea - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Obstructive Sleep Apnea - Products under Development by Companies 12 Obstructive Sleep Apnea - Companies Involved in Therapeutics Development 13 Galleon Pharmaceuticals Inc 13 RespireRx Pharmaceuticals Inc 14 SK Biopharmaceuticals Co Ltd 15 Vivus Inc 16 Obstructive Sleep Apnea - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Combination Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 24 Drug Profiles 25 (phentermine + topiramate) ER - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 dronabinol - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 GAL-475 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 GAL-475 Backups - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 SKL-N05 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Obstructive Sleep Apnea - Dormant Projects 38 Obstructive Sleep Apnea - Discontinued Products 39 Obstructive Sleep Apnea - Product Development Milestones 40 Featured News & Press Releases 40 Sep 26, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea 40 Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting 40 Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA 41 May 14, 2015: VIVUS Announces Scientific Presentations 42 May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists 43 Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies 43 Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules 44 Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa 45 Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa 46 Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for Obstructive Sleep Apnea, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Obstructive Sleep Apnea - Pipeline by Galleon Pharmaceuticals Inc, H2 2016 13 Obstructive Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc, H2 2016 14 Obstructive Sleep Apnea - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 15 Obstructive Sleep Apnea - Pipeline by Vivus Inc, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Assessment by Combination Products, H2 2016 18 Number of Products by Stage and Target, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 24 Obstructive Sleep Apnea - Dormant Projects, H2 2016 38 Obstructive Sleep Apnea - Discontinued Products, H2 2016 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.